This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Apr 2011

Gilead & MicroDose Ink RSV Deal

Gilead Sciences said Wednesday it signed a licensing deal with MicroDose Therapeutx for an experimental respiratory syncytial virus treatment.

Gilead Sciences and MicroDose Therapeutx have inked an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).


According to the agreement, MicroDose will receive an upfront payment and research funding to support development of MDT-637 through Phase IIa trials, after which Gilead can assume full development responsibility. MicroDose is also eligible to receive additional payments based upon the achievement of certain development, regulatory and commercial milestones, as well as development fees and royalties on potential sales.


"This strategic collaboration is a significant milestone i

Related News